Brain Natriuretic Peptide: Diagnostic and Therapeutic Implications in Pulmonary Arterial Hypertension

 

 Buy Article Permissions and Reprints

ABSTRACT

Brain or B-type natriuretic peptide (BNP) is one of the new biomarkers employed within the last decade to help clarify difficult cardiovascular problems. Plasma BNP is elevated in cardiac ventricular dysfunction and plays a key role in protecting the body from volume overload by maintaining renal function and sodium balance. Studies in patients with pulmonary arterial hypertension (PAH) have demonstrated that plasma BNP levels are raised proportionally to the extent of right ventricular (RV) dysfunction. There is growing evidence that BNP may be a potential biomarker for PAH in screening for occult disease, diagnostic evaluation, prognosis, and estimating a response to therapy. Additionally, augmentation of the natriuretic peptide system through exogenous administration of BNP or by preventing its degradation may be a promising option for the management of decompensated RV failure. Because plasma BNP levels rise in a variety of cardiopulmonary conditions and are affected by several physiological factors, BNP interpretation must not occur in isolation but rather within the context of good clinical judgment.

REFERENCES

• 1 Hatano S, Strasser T Primary pulmonary hypertension: report on a WHO meeting. Geneva; World Health Organization 1975
  Google Scholar
• 2 Simonneau G, Galie N, Rubin L J et al.. Clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(suppl 12) 5S-12S
  CrossrefPubMedGoogle Scholar
• 3 Maisel A S, Krishnaswamy P, Nowak R M et al.. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 161-167
  CrossrefPubMedGoogle Scholar
• 4 Yasue H, Yoshimura M, Sumida H et al.. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.  Circulation. 1994;  90 195-203
  CrossrefPubMedGoogle Scholar
• 5 Luchner A, Stevens T L, Borgeson D D et al.. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure.  Am J Physiol. 1998;  274 H1684-H1689
  PubMedGoogle Scholar
• 6 Hama N, Itoh H, Shirakami G et al.. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction.  Circulation. 1995;  92 1558-1564
  PubMedGoogle Scholar
• 7 Goetze J P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited.  Clin Chem. 2004;  50 1503-1510
  CrossrefPubMedGoogle Scholar
• 8 Burnett Jr J C, Kao P C, Hu D C et al.. Atrial natriuretic peptide elevation in congestive heart failure in the human.  Science. 1986;  231 1145-1147
  CrossrefPubMedGoogle Scholar
• 9 Levin E R, Gardner D G, Samson W K. Natriuretic peptides.  N Engl J Med. 1998;  339 321-328
  CrossrefPubMedGoogle Scholar
• 10 Nagaya N, Nishikimi T, Okano Y et al.. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension.  J Am Coll Cardiol. 1998;  31 202-208
  PubMedGoogle Scholar
• 11 Leuchte H H, Holzapfel M, Baumgartner R A et al.. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.  J Am Coll Cardiol. 2004;  43 764-770
  CrossrefPubMedGoogle Scholar
• 12 Leuchte H H, Neurohr C, Baumgartner R et al.. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.  Am J Respir Crit Care Med. 2004;  170 360-365
  CrossrefPubMedGoogle Scholar
• 13 Ishii J, Nomura M, Ito M et al.. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease.  Clin Chim Acta. 2000;  301 19-30
  CrossrefPubMedGoogle Scholar
• 14 Lubien E, DeMaria A, Krishnaswamy P et al.. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.  Circulation. 2002;  105 595-601
  CrossrefPubMedGoogle Scholar
• 15 Yamamoto K, Burnett Jr J C, Jougasaki M et al.. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.  Hypertension. 1996;  28 988-994
  PubMedGoogle Scholar
• 16 Fujii T, Otsuka T, Tanaka S et al.. Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide.  Respiration . 1999;  66 212-219
  CrossrefPubMedGoogle Scholar
• 17 de Lemos J A, Morrow D A, Bentley J H et al.. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.  N Engl J Med. 2001;  345 1014-1021
  CrossrefPubMedGoogle Scholar
• 18 Sabatine M S, Morrow D A, de Lemos J A et al.. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.  J Am Coll Cardiol. 2004;  44 1988-1995
  CrossrefPubMedGoogle Scholar
• 19 Tulevski I I, Hirsch A, Sanson B J et al.. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism.  Thromb Haemost. 2001;  86 1193-1196
  PubMedGoogle Scholar
• 20 Hasegawa K, Fujiwara H, Doyama K et al.. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy.  Circulation. 1993;  88 372-380
  PubMedGoogle Scholar
• 21 Ikeda T, Matsuda K, Itoh H et al.. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis.  Am Heart J. 1997;  133 307-314
  PubMedGoogle Scholar
• 22 Masters R G, Davies R A, Veinot J P et al.. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans.  Circulation. 1999;  100 287-291
  PubMedGoogle Scholar
• 23 Charpentier J, Luyt C E, Fulla Y et al.. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis.  Crit Care Med. 2004;  32 660-665
  CrossrefPubMedGoogle Scholar
• 24 Borghi C, Esposti D D, Immordino V et al.. Relationship of systemic hemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia.  Am J Obstet Gynecol. 2000;  183 140-147
  CrossrefPubMedGoogle Scholar
• 25 Berendes E, Walter M, Cullen P et al.. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage.  Lancet. 1997;  349 245-249
  CrossrefPubMedGoogle Scholar
• 26 McCullough P A, Duc P, Omland T et al.. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.  Am J Kidney Dis. 2003;  41 571-579
  CrossrefPubMedGoogle Scholar
• 27 Akiba T, Tachibana K, Togashi K et al.. Plasma human brain natriuretic peptide in chronic renal failure.  Clin Nephrol. 1995;  44(Suppl 1) S61-S64
  PubMedGoogle Scholar
• 28 Totsune K, Takahashi K, Satoh F et al.. Urinary immunoreactive brain natriuretic peptide in patients with renal disease.  Regul Pept. 1996;  63 141-147
  CrossrefPubMedGoogle Scholar
• 29 Haug C, Metzele A, Steffgen J et al.. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure.  Horm Metab Res. 1994;  26 246-249
  PubMedGoogle Scholar
• 30 Cataliotti A, Malatino L S, Jougasaki M et al.. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.  Mayo Clin Proc. 2001;  76 1111-1119
  PubMedGoogle Scholar
• 31 Redfield M M, Rodeheffer R J, Jacobsen S J et al.. Plasma brain natriuretic peptide concentration: impact of age and gender.  J Am Coll Cardiol. 2002;  40 976-982
  CrossrefPubMedGoogle Scholar
• 32 Wang T J, Larson M G, Levy D et al.. Impact of age and sex on plasma natriuretic peptide levels in healthy adults.  Am J Cardiol. 2002;  90 254-258
  CrossrefPubMedGoogle Scholar
• 33 Wang T J, Larson M G, Levy D et al.. Impact of obesity on plasma natriuretic peptide levels.  Circulation. 2004;  109 594-600
  CrossrefPubMedGoogle Scholar
• 34 Mehra M R, Uber P A, Park M H et al.. Obesity and suppressed B-type natriuretic peptide levels in heart failure.  J Am Coll Cardiol. 2004;  43 1590-1595
  CrossrefPubMedGoogle Scholar
• 35 McCord J, Mundy B J, Hudson M P et al.. Relationship between obesity and B-type natriuretic peptide levels.  Arch Intern Med. 2004;  164 2247-2252
  CrossrefPubMedGoogle Scholar
• 36 Sarzani R, Dessi-Fulgheri P, Paci V M et al.. Expression of natriuretic peptide receptors in human adipose and other tissues.  J Endocrinol Invest. 1996;  19 581-585
  PubMedGoogle Scholar
• 37 Pemberton C J, Johnson M L, Yandle T G et al.. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload.  Hypertension. 2000;  36 355-359
  PubMedGoogle Scholar
• 38 Lainchbury J G, Campbell E, Frampton C M et al.. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath.  J Am Coll Cardiol. 2003;  42 728-735
  CrossrefPubMedGoogle Scholar
• 39 Battle R W, Davitt M A, Cooper S M et al.. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.  Chest. 1996;  110 1515-1519
  CrossrefPubMedGoogle Scholar
• 40 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.  Rheumatology (Oxford). 2001;  40 453-459
  CrossrefPubMedGoogle Scholar
• 41 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
  CrossrefPubMedGoogle Scholar
• 42 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
  PubMedGoogle Scholar
• 43 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
  CrossrefPubMedGoogle Scholar
• 44 Oudiz R J, Schilz R J, Barst R J et al.. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.  Chest. 2004;  126 420-427
  CrossrefPubMedGoogle Scholar
• 45 Allanore Y, Borderie D, Meune C et al.. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.  Arthritis Rheum. 2003;  48 3503-3508
  CrossrefPubMedGoogle Scholar
• 46 McQuillan B M, Picard M H, Leavitt M et al.. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects.  Circulation. 2001;  104 2797-2802
  CrossrefPubMedGoogle Scholar
• 47 Denton C P, Cailes J B, Phillips G D et al.. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.  Br J Rheumatol. 1997;  36 239-243
  CrossrefPubMedGoogle Scholar
• 48 Rubin L J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126 4S-6S
  CrossrefPubMedGoogle Scholar
• 49 Galie N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
  CrossrefPubMedGoogle Scholar
• 50 Barst R J, McGoon M, Torbicki A et al.. Diagnosis and differential assessment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 40S-47S
  CrossrefPubMedGoogle Scholar
• 51 Reynolds E W. Brain-type natriuretic Peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn: in reply.  Pediatrics. 2005;  115 1112
  PubMedGoogle Scholar
• 52 Reynolds E W, Ellington J G, Vranicar M et al.. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn.  Pediatrics. 2004;  114 1297-1304
  CrossrefPubMedGoogle Scholar
• 53 Nagaya N, Nishikimi T, Uematsu M et al.. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.  Circulation. 2000;  102 865-870
  CrossrefPubMedGoogle Scholar
• 54 Park M H, Scott R L, Uber P A et al.. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension.  Congest Heart Fail. 2004;  10 221-225
  PubMedGoogle Scholar
• 55 Wilkins M R, Paul G A, Strange J W et al.. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study.  Am J Respir Crit Care Med. 2005;  171 1292-1297
  CrossrefPubMedGoogle Scholar
• 56 Francis G S, Goldsmith S R, Levine T B et al.. The neurohumoral axis in congestive heart failure.  Ann Intern Med. 1984;  101 370-377
  PubMedGoogle Scholar
• 57 Colucci W S, Elkayam U, Horton D P et al.. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.  N Engl J Med. 2000;  343 246-253
  CrossrefPubMedGoogle Scholar
• 58 Publication Committee for the VMAC Investigators . Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.  JAMA. 2002;  287 1531-1540
  CrossrefPubMedGoogle Scholar
• 59 Yancy C W, Saltzberg M T, Berkowitz R L et al.. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).  Am J Cardiol. 2004;  94 595-601
  CrossrefPubMedGoogle Scholar
• 60 Michaels A D, Chatterjee K, Madden J et al.. Hemodynamic effects of intravenous nesiritide in patients with pulmonary hypertension [abstract].  J Am Coll Cardiol. 2004;  43(Suppl 5A) 192A
  PubMedGoogle Scholar
• 61 Kurian D C, Wagner I J, Klapholz M. Nesiritide in pulmonary hypertension.  Chest. 2004;  126 302-305
  CrossrefPubMedGoogle Scholar
• 62 Corti R, Burnett Jr J C, Rouleau J L et al.. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?.  Circulation. 2001;  104 1856-1862
  PubMedGoogle Scholar
• 63 Packer M, Califf R M, Konstam M A et al.. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).  Circulation. 2002;  106 920-926
  CrossrefPubMedGoogle Scholar
• 64 Hoeper M M, Oudiz R J, Peacock A et al.. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.  J Am Coll Cardiol. 2004;  43 48S-55S
  CrossrefPubMedGoogle Scholar

Victor F TapsonM.D. 

Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center

Box 31175, Durham, NC 27710

Email: tapso001@mc.duke.edu